

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)**ATTY. DOCKET NO.**

11767-032-999

**APPLICATION NO.**

09/623,543

**APPLICANT**

Bridon et al.

**FILING DATE**

September 5, 2000

**ART UNIT**

1642

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	5,424,286	06/13/95	Eng	
	A02	60/037,412	02/05/97	Drucker	
	A03	60/103,498	10/08/98	Coolidge <i>et al.</i>	
	A04	60/132,018	4/30/99	Prickett <i>et al.</i>	
	A05	6,284,725 B1	09/04/01	Coolidge <i>et al.</i>	
	A06	6,451,974 B1	09/17/02	Hansen	
	A07	6,723,530 B1	04/20/04	Drucker	
	A08	6,767,887 B1	07/27/04	Hoffman <i>et al.</i>	
	A09	60/152,681	09/07/99	Ezrin <i>et al.</i>	
	A10	2003/0170250	09/11/03	Ezrin <i>et al.</i>	
	A11	2004/0156859	08/12/04	Ezrin <i>et al.</i>	
	A12	2004/0266673	12/30/04	Bakis <i>et al.</i>	
	A13	2005/0065075	03/24/05	Erickson <i>et al.</i>	
	A14	2005/0070475	03/31/05	Bridon <i>et al.</i>	
	A15	2005/0176641	08/11/05	Bakis <i>et al.</i>	
	A16	2005/0176643	08/11/05	Bridon <i>et al.</i>	
	A17	2006/0058235	03/16/06	Bridon <i>et al.</i>	
	A18	2006/0135426	06/22/06	Bridon <i>et al.</i>	
	A19	2006/0135428	06/22/06	Bridon <i>et al.</i>	
	A20	2006/0217304	09/28/06	Bridon <i>et al.</i>	
	A21	2006/0241019	10/26/06	Bridon <i>et al.</i>	
	A22	2007/0207958	09/06/07	Bridon <i>et al.</i>	
	A23	2007/0269863	11/22/07	Bridon <i>et al.</i>	
	A24	5,840,733	11/24/98	Krantz <i>et al.</i>	
	A25	5,843,440	12/01/98	Pouletty <i>et al.</i>	
	A26	5,942,620	08/24/99	Krantz <i>et al.</i>	
	A27	6,087,375	08/11/00	Bridon <i>et al.</i>	
	A28	6,103,233	08/15/00	Pouletty <i>et al.</i>	
	A29	6,277,583	08/21/01	Krantz <i>et al.</i>	

NYI-4069369v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11767-032-999	<b>APPLICATION NO.</b> 09/623,543
	<b>APPLICANT</b> Bridon et al.	
	<b>FILING DATE</b> September 5, 2000	<b>ART UNIT</b> 1642

### U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A30	6,277,863	08/21/01	Krantz <i>et al.</i>	
	A31	6,403,324	06/11/02	Krantz <i>et al.</i>	
	A32	6,437,092	08/20/02	Ezrin <i>et al.</i>	
	A33	6,440,417	08/27/02	Thibaudeau <i>et al.</i>	
	A34	6,451,974	09/17/02	Hansen	
	A35	6,602,981	08/05/03	Ezrin <i>et al.</i>	
	A36	6,610,825	08/26/03	Ezrin <i>et al.</i>	
	A37	6,706,892	03/16/04	Ezrin <i>et al.</i>	
	A38	6,887,470	05/03/05	Bridon <i>et al.</i>	
	A39	7,090,851	08/15/06	Bridon <i>et al.</i>	
	A40	7,112,567	09/26/06	Bridon <i>et al.</i>	
	A41	7,166,695	01/23/07	Krantz <i>et al.</i>	
	A42	7,256,253	08/14/07	Bridon <i>et al.</i>	
	A43	7,268,113	09/11/07	Bridon <i>et al.</i>	
	A44	7,307,148	12/01/07	Bousquet Gagnon <i>et al.</i>	
	A45	6,107,489	08/22/00	Krantz <i>et al.</i>	
	A46	6,329,336	12/11/01	Bridon <i>et al.</i>	
	A47	6,500,918	12/31/02	Ezrin <i>et al.</i>	
	A48	2004/0127398	07/01/04	Bridon <i>et al.</i>	
	A49	2004/0138100	07/15/04	Bridon <i>et al.</i>	
	A50	09/424,571	11/22/99	Ezrin <i>et al.</i>	
	A51	4,462,941	07/31/1984	Lee <i>et al.</i>	
	A52	5,493,007	02/20/1996	Burnier <i>et al.</i>	
	A53	5,580,853	12/03/1996	Sytkowski	
	A54	5,654,276	08/05/1997	Barrett <i>et al.</i>	
	A55	5,843,440	12/01/1998	Pouletty <i>et al.</i>	
	A56	6,849,714	02/01/2005	Bridon <i>et al.</i>	
	A57	6,514,500	02/04/2003	Bridon <i>et al.</i>	
	A58	6,593,295	07/15/2003	Bridon <i>et al.</i>	

NYI-4069369v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11767-032-999	<b>APPLICATION NO.</b> 09/623,543
	<b>APPLICANT</b> Bridon et al.	
	<b>FILING DATE</b> September 5, 2000	<b>ART UNIT</b> 1642

### U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear /
	A59	6,821,949	11/23/2004	Bridon <i>et al.</i>	
	A60	6,329,336	12/11/2001	Bridon <i>et al.</i>	
	A61	6,887,849	05/03/2005	Bridon et al.	

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 00/69902	05/17/00	ConjuChem, Inc.		
	B02	WO 00/69911	11/23/2000	ConjuChem, Inc.		
	B03	WO 01/017568	09/07/00	ConjuChem, Inc.		
	B04	WO 01/017614	09/07/00	ConjuChem, Inc.		
	B05	WO 02/062844	01/02/02	ConjuChem, Inc.		
	B06	WO 02/066511	02/15/02	ConjuChem, Inc.		
	B07	WO 02/096935	05/31/02	ConjuChem, Inc.		
	B08	WO 04/011498	07/29/03	ConjuChem, Inc.		
	B09	WO 05/012346	07/26/04	ConjuChem, Inc.		
	B10	WO 05/103087	04/22/05	ConjuChem Biotechnologies Inc.		
	B11	WO 05/108418	06/15/05	ConjuChem Biotechnologies Inc.		
	B12	WO 07/053946	11/09/06	ConjuChem Biotechnologies Inc.		
	B13	WO 07/071068	12/22/06	ConjuChem Biotechnologies Inc.		
	B14	WO 91/08220	06/13/91	Houen Gunnar		
	B15	WO 97/25074	01/07/97	Redcell Canada, Inc.		
	B16	WO 97/29372	01/07/97	Redcell Inc.		
	B17	WO 97/46584	12/11/97	Boehringer Mannheim GmbH		
	B18	WO 98/00171	06/30/97	ConjuChem, Inc.		
	B19	WO 98/05351	02/12/98	Amylin Pharmaceuticals, Inc.		
	B20	WO 98/11437	09/16/97	ConjuChem, Inc.		
	B21	WO 99/07404	02/18/99	Amylin Pharmaceuticals, Inc.		
	B22	WO 99/24071	05/20/99	ConjuChem, Inc.		

NYI-4069369v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 11767-032-999	<b>APPLICATION NO.</b> 09/623,543
	<b>APPLICANT</b> Bridon et al.	
	<b>FILING DATE</b> September 5, 2000	<b>ART UNIT</b> 1642

### FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B23	WO 99/24076	11/06/98	ConjuChem, Inc.		
	B24	WO 99/24462	05/20/1999	ConjuChem, Inc.		
	B25	WO 99/25727	05/27/99	Amylin Pharmaceuticals, Inc.		
	B26	WO 99/25728	05/27/99	Amylin Pharmaceuticals, Inc.		
	B27	WO 99/46283	09/16/99	Zealand Pharmaceuticals A/S		

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	Alberts <i>et al.</i> , 1994, <i>Molecular Biology of the Cell, Third Edition</i> , New York: Garland Publishing, page G19.	
	C02	Barragán <i>et al.</i> , 1996, "Interactions of Exendin(9-39) with the Effects of Glucagon-Like Peptide-1-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats," 67:63-68.	
	C03	Binder <i>et al.</i> , 1984, "Insulin Pharmacokinetics," <i>Diabetes Care</i> 7:188-199.	
	C04	Breton <i>et al.</i> , 1995, "Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin," <i>Eur. J. Biochem.</i> 231:563-569.	
	C05	<i>Catalog, Shearwater Polymers, Inc., Functionalized Biocompatible Polymers for Research, Polyethylene Glycol Derivatives</i> , 1993.	
	C06	Cooper, 1997, <i>The Cell A Molecular Approach</i> , ASM Press (Washington, DC), Sinauer Associates, Inc. (Sunderland, MA), 296-298, 648.	
	C07	Edwards <i>et al.</i> , 1999 (December), "Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans," <i>Diabetes</i> 48: 86-93.	
	C08	Eng <i>et al.</i> , 1990, "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <i>J. Biol. Chem.</i> 265:20259-20262.	
	C09	Eng <i>et al.</i> , 1992, "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," <i>J. Biol. Chem.</i> 267:7402-7405.	
	C10	Gennaro, ed., 1995, <i>Remington: The Science and Practice of Pharmacy, 19<sup>th</sup> Edition</i> , 898, 931-94.	
	C11	Göke <i>et al.</i> , 1989, "Characterization of the Receptor for Glucagon-like-peptide-1(7-36)amide on Plasma Membranes from Rat Insulinoma-derived Cells by Covalent Cross-Linking," <i>J. Mol. Endocrinol.</i> 2:93-98.	
	C12	Göke <i>et al.</i> , 1992, "Solubilization of Active GLP-1 (7-36)amide Receptors From RINm5F Plasma Membranes," <i>FEBS Lett.</i> 300:232-236.	
	C13	Göke <i>et al.</i> , 1993, "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting $\beta$ -Cells," <i>J. Biol. Chem.</i> 268(26):19650-19655.	
	C14	Göke <i>et al.</i> , 1995, "Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that Exendin-4 is a Ligand of Brain GLP-1 Binding Sites," <i>Eur. J. Neurosci.</i> 7:2294-2300.	
	C15	Gombotz and Pettit, 1995, "Biodegradable Polymers for Protein and Peptide Drug Delivery," <i>Bioconjugate Chem.</i> 6:332-351.	
	C16	Grand, 1989, "Acylation of Viral and Eukaryotic Proteins," <i>Biochem J.</i> 258:625-638.	

NYI-4069369v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

11767-032-999

**APPLICATION NO.**

09/623,543

**APPLICANT**

Bridon et al.

**FILING DATE**

September 5, 2000

**ART UNIT**

1642

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C17	Grieg et al., 1999 (January), "Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects of Blood Glucose Concentrations," <i>Diabetologia</i> 42:45-50.	
	C18	Harlow & Lane, 1988, <i>Antibodies: A Laboratory Manual</i> , pp. 101, 129.	
	C19	Hoshino et al., 1984, "Primary Structure of Helodermin, a VIP-Secretin-Like Peptide Isolated from Gila Monster Venom," <i>FEBS Lett.</i> 178:233-239	
	C20	Isoai et al., 1993, "A Potent Anti-Metastatic Activity of Tumor Invasion-Inhibiting Factor-2 and Albumin Conjugate," <i>Biochem. Biophys. Res. Comm.</i> 192:7-14.	
	C21	Lewis, 1997, <i>Hawley's Condensed Chemical Dictionary, 13<sup>th</sup> Edition</i> , John Wiley & Sons, Inc. (New York), 487, 815.	
	C22	Mattson et al., 1993, "A Practical Approach to Crosslinking," <i>Mol. Biol. Reports</i> 17:167-183.	
	C23	Petrella et al., 1999 (May), "Development and Validation of an Immunoradiometric Assay (IRMA) for the Quantitation of Exendin-4 in Plasma and Its Application to Preclinical Toxicity and Phase I Clinical Evaluations," <i>Diabetes</i> 48:A425.	
	C24	Poznansky & Juliano, 1984, "Biological Approaches to the Controlled Delivery of Drugs: A Critical Review," <i>Pharmacological Reviews</i> 36:277-335.	
	C25	Raufman, 1996, "Bioactive Peptides from Lizard Venoms," <i>Regulatory Peptides</i> 61:1-18.	
	C26	Richter et al., 1991, "Characterization of Glucagon-Like Peptide-I(7-36)amide Receptors of Rat Lung Membranes by Covalent Cross-Linking," <i>FEBS Lett.</i> 280:247-250	
	C27	Robberecht et al., 1985, "Immunoreactive Helodermin-like Peptides in Rat: A New Class of Mammalian Neuropeptides Related to Secretin and VIP" <i>Biochem Biophys. Res. Comm.</i> 130: 333-342.	
	C28	Schirra et al., 1998, "Exendin(9-39)amide is an Antagonist of Glucagon-Like Peptide-I(7-36)amide in Humans," <i>J. Clin. Invest.</i> 101:1421-1430.	
	C29	Schmidtler et al., 1994, "Rat Parietal Cell Receptors for GLP-1-(7-36) Amide: Northern Blot, Cross-Linking, and Radioligand Binding," <i>Am. J. Physiol.</i> 267:G423-432.	
	C30	Syed et al., 1997, "Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin," <i>Blood</i> 89:3243-3252.	
	C31	Vandermeers et al., 1984, "Purification of a Novel Pancreatic Secretory Factor (PSF) and a Novel Peptide with VIP- and Secretin-like Properties (Helodermin) from Gila Monster Venom," <i>FEBS Lett.</i> 166:273-276.	
	C32	Vandermeers et al., 1987, "Chemical, Immunological and Biological Properties of Peptides Like Vasoactive-Intestinal-Peptide and Peptide-Histidine-Isoleucinamide Extracted from the Venom of Two Lizards ( <i>Heloderma horridum</i> and <i>Heloderma suspectum</i> )," <i>Eur. J. Biochem.</i> 164:321-327.	
	C33	Yeh et al., 1992, "Design of Yeast-Secreted Albumin derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," <i>Proc. Natl. Acad. Sci. USA</i> 89:1904-1908.	
	C34	Meloun et al., 1975, "Complete Amino Acid Sequence of Human Serum Albumin," <i>FEBS Letters</i> 58, 134-137	
	C35	Davis et al., 1991, "Reduction of Immunogenicity and extension of circulating half-life of peptides and proteins," <i>Peptide and Protein Drug Delivery</i> , Marcel Dekker, Inc., NY, NY, 831-864	
	C36	Paige et al., 1995, "Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol," <i>Pharm. Research.</i> , Vol. 12(12), 1883-1888	
	C37	Poznansky, 1983, "Enzyme-protein conjugates: new possibilities for enzyme therapy," <i>Pharm. Ther.</i> , Vol. 21, pp. 53-76	
	C38	Poznansky et al., 1988, "Growth hormone-albumin conjugates reduced renal toxicity and altered plasma clearance," <i>Federation of European Biochemical Societies</i> , Vol. 239(1), pp 18-22	

NYI-4069369v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.